Biological Assembly 1  

Global Symmetry: Asymmetric - C1 
Global Stoichiometry: Hetero 3-mer - A1B1C1 Pseudo Symmetry: Asymmetric - C1 
Pseudo Stoichiometry: Hetero 3-mer - A2B1 

Biological assembly 1 assigned by authors and generated by PISA (software)

Biological Assembly Evidence: isothermal titration calorimetry

Macromolecule Content

• Total Structure Weight: 47.53 kDa 
• Atom Count: 3,945 
• Modelled Residue Count: 444 
• Deposited Residue Count: 444 
• Unique protein chains: 3

 6LRA

The complex structure of PHF core domain peptide of tau and antibody's Fab domain.

• PDB DOI: 10.2210/pdb6LRA/pdb

• Classification: IMMUNE SYSTEM
• Organism(s): Mus musculus, Homo sapiens
• Mutation(s): No 


• Deposited: 2020-01-15 Released: 2020-08-26 
• Deposition Author(s): Tomohiro, T., Kouki, S., Tomohiro, S., Takahiro, T., Katsushiro, M., Yasuko, I., Katsuhiko, M., Taizo, T., Toshimitsu, I., Koji, T.

---

Experimental Data Snapshot

• Method: X-RAY DIFFRACTION
• Resolution: 1.90 Å
• R-Value Free: 0.249 
• R-Value Work: 0.188 
• R-Value Observed: 0.191 

Literature

Crystal structure of the human tau PHF core domain VQIINK complexed with the Fab domain of monoclonal antibody Tau2r3.

Tsuchida, T., Susa, K., Kibiki, T., Tsuchiya, T., Miyamoto, K., In, Y., Minoura, K., Taniguchi, T., Ishida, T., Tomoo, K.

(2020) FEBS Lett 

• PubMed: 32282060 
• DOI: 10.1002/1873-3468.13791
• Primary Citation of Related Structures:  
  6LRA


• PubMed Abstract: 
  

Neurofibrillary tangles formed by abnormally aggregated tau protein are a histopathological feature of tauopathies. A tau aggregation inhibitor is a potential therapeutic agent for tauopathies. In this study, we prepared a monoclonal antibody for tau, monoclonal antibody to tau protein (Tau2r3), using as epitope the ²⁷² GGKVQIINKKLD ²⁸³ peptide in the microtubule-binding domain of tau, the key region mediating tau aggregation. We show that Tau2r3 clearly inhibits tau aggregation. To analyze the inhibition mechanism of Tau2r3, we solved the crystal structure of the Fab domain of Tau2r3 (Fab2r3) in complex with the VQIINK peptide. In the Fab2r3-VQIINK structure, the second and sixth polar residues and the fourth hydrophobic residue of VQIINK are crucial for binding to Fab2r3. The structural data for the Fab2r3-VQIINK complex could contribute to the design of new tau aggregation inhibitors.

---

Organizational Affiliation: 

Department of Physical Chemistry, Osaka University of Pharmaceutical Sciences, Takatsuki, Japan.

Macromolecules

Entity ID: 1
Molecule	Chains	Sequence Length	Organism	Details	Image
Fab Heavy Chain	A [auth H]	218	Mus musculus	Mutation(s): 0

Entity ID: 2
Molecule	Chains	Sequence Length	Organism	Details	Image
Fab Light Chain	B [auth L]	220	Mus musculus	Mutation(s): 0

Entity ID: 3
Molecule	Chains	Sequence Length	Organism	Details	Image
VQIINK	C	6	Homo sapiens	Mutation(s): 0  Gene Names: MAPT, MAPTL, MTBT1, TAU
UniProt & NIH Common Fund Data Resources
Find proteins for P10636 (Homo sapiens) Explore P10636  Go to UniProtKB:  P10636
PHAROS:  P10636

Experimental Data & Validation

Experimental Data

• Method: X-RAY DIFFRACTION
• Resolution: 1.90 Å
• R-Value Free: 0.249 
• R-Value Work: 0.188 
• R-Value Observed: 0.191 
• Space Group: P 2₁ 2₁ 2₁

Unit Cell:

Length ( Å )	Angle ( ˚ )
a = 59.65	α = 90
b = 70.68	β = 90
c = 118.37	γ = 90

Software Package:

Software Name	Purpose
REFMAC	refinement
PDB_EXTRACT	data extraction
Coot	model building
MOLREP	phasing
CrystalClear	data reduction
CrystalClear	data scaling

Structure Validation

Entry History 

Deposition Data

• Released Date: 2020-08-26 
Deposition Author(s): Tomohiro, T., Kouki, S., Tomohiro, S., Takahiro, T., Katsushiro, M., Yasuko, I., Katsuhiko, M., Taizo, T., Toshimitsu, I., Koji, T.

Revision History  

• Version 1.0: 2020-08-26
  Type: Initial release